FY2016 EPS Estimates for Chimerix Inc. (CMRX) Decreased by FBR & Co
Chimerix Inc. (NASDAQ:CMRX) – FBR & Co lowered their FY2016 earnings per share (EPS) estimates for Chimerix in a research note issued on Monday. FBR & Co analyst E. White now anticipates that the firm will earn ($1.66) per share for the year, down from their prior forecast of ($1.62). FBR & Co has a “Hold” rating on the stock. FBR & Co also issued estimates for Chimerix’s Q4 2016 earnings at ($0.35) EPS, FY2017 earnings at ($1.48) EPS and FY2018 earnings at ($1.53) EPS.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Chimerix had a negative return on equity of 32.09% and a negative net margin of 1,451.99%.
A number of other research firms have also recently commented on CMRX. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Tuesday, October 4th. Piper Jaffray Cos. set a $12.00 target price on Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 target price on shares of Chimerix in a research note on Tuesday, August 9th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.32.
Chimerix (NASDAQ:CMRX) opened at 4.62 on Wednesday. Chimerix has a 1-year low of $3.50 and a 1-year high of $42.24. The company’s market cap is $213.51 million. The stock’s 50 day moving average price is $4.80 and its 200 day moving average price is $4.61.
Hedge funds have recently modified their holdings of the company. Virginia Retirement Systems ET AL purchased a new stake in shares of Chimerix during the second quarter valued at approximately $103,000. Raymond James & Associates raised its stake in shares of Chimerix by 6.9% in the second quarter. Raymond James & Associates now owns 27,083 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,757 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in shares of Chimerix during the second quarter valued at approximately $112,000. BlackRock Advisors LLC raised its stake in shares of Chimerix by 19.4% in the third quarter. BlackRock Advisors LLC now owns 22,213 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 3,611 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of Chimerix during the second quarter valued at approximately $159,000. 66.25% of the stock is owned by institutional investors.
In related news, Director John M. Leonard sold 5,000 shares of Chimerix stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.03, for a total value of $25,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider M Michelle Berrey acquired 22,417 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The stock was purchased at an average cost of $4.47 per share, with a total value of $100,203.99. Following the acquisition, the insider now directly owns 281,238 shares of the company’s stock, valued at $1,257,133.86. The disclosure for this purchase can be found here. 10.50% of the stock is owned by corporate insiders.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.